User: Guest  Login
Title:

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Document type:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Article
Author(s):
Petrylak, Daniel P; Vogelzang, Nicholas J; Budnik, Nikolay; Wiechno, Pawel Jan; Sternberg, Cora N; Doner, Kevin; Bellmunt, Joaquim; Burke, John M; de Olza, Maria Ochoa; Choudhury, Ananya; Gschwend, Juergen E; Kopyltsov, Evgeny; Fléchon, Aude; Van As, Nicolas; Houédé, Nadine; Barton, Debora; Fandi, Abderrahim; Jungnelius, Ulf; Li, Shaoyi; de Wit, Ronald; Fizazi, Karim
Abstract:
Patients with metastatic castration-resistant prostate cancer have few treatment options. We investigated the safety and efficacy of lenalidomide, an immunomodulatory agent with anti-angiogenic properties, in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.In this randomised, double-blind, placebo-controlled, phase 3 study, we randomly assigned chemotherapy-naive patients with progressive metastatic castration-resistan...     »
Journal title abbreviation:
Lancet Oncol
Year:
2015
Journal volume:
16
Journal issue:
4
Pages contribution:
417-25
Language:
eng
Fulltext / DOI:
doi:10.1016/S1470-2045(15)70025-2
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/25743937
Print-ISSN:
1470-2045
TUM Institution:
Urologische Klinik und Poliklinik
 BibTeX